Human Blood Cell Disorders Clinical Trial
Official title:
Human Blood Cell Disorders Tissue Bank
| NCT number | NCT00902447 |
| Other study ID # | 08-202 |
| Secondary ID | |
| Status | Recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | April 2009 |
| Est. completion date | January 2035 |
| Verified date | March 2024 |
| Source | Northwell Health |
| Contact | Yasmine Kieso, MSCR |
| ykieso[@]northwell.edu | |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The Human Blood Cell Disorder Tissue Bank will provide a convenient, comprehensive source of tissue containing populations of human blood cells from patients with various types of lymphoid, myeloid, and erythroid proliferative diseases as well as other associated conditions. The tissue bank will continue to be an invaluable asset for understanding of the biology of multiple blood cell disorders involving several cell types as well as the physiology of normal cellular counterparts affected in these disorders. Internal and external investigators will be able to utilize this tissue to test hypotheses relating to the immunologic, virologic, genetic, and molecular properties of these abnormal cells as well as normal cells from normal unaffected family members or normal aged matched subjects to provide better comparisons.
| Status | Recruiting |
| Enrollment | 10000 |
| Est. completion date | January 2035 |
| Est. primary completion date | January 2030 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 100 Years |
| Eligibility | Inclusion Criteria: - Participants or participant's Legally Authorized Representatives (LAR) must be able to understand and render voluntary, written informed consent. - Patients must be able to contribute the required amount of blood and/or tissue without compromising their well-being or care. - Participants must be willing to be contacted again for consideration of additional studies in the future, such as a blood draw or another action (e.g., bone marrow aspiration and/or biopsy) that would be done as part of their standard of care. Exclusion Criteria: - Patients who are known to be anemic, with hemoglobin <8.0g/dl. - Patients who are known to be infected with HIV. |
| Country | Name | City | State |
|---|---|---|---|
| United States | The Feinstein Institute for Medical Research | Manhasset | New York |
| Lead Sponsor | Collaborator |
|---|---|
| Northwell Health |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Accumulate tissue from patients with various blood disorders, including but not restricted to lymphoproliferative, myeloproliferative, and erythroproliferative conditions. | Indefinite | ||
| Secondary | Develop a database of at least 10,000 subjects who have donated samples for research as well as DNA banking, and who are willing to be contacted again for consideration of additional studies in the future. | Indefinite |